COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Amendments are illustrated by showing deletions ~~by strikethrough~~ or by [[double brackets]] for deletions of five or fewer characters and additions by underlining)

Claims 1-22 (canceled)

23 (currently amended): A compound of the formula:



wherein

A^1 is a D- or L-isomer of an aromatic amino acid, or is deleted;

~~A^2 is a D aromatic amino acid,~~

~~A^3 is an aromatic amino acid;~~

~~A^6 is Thr, Thr(Bzl), Gly, Ser, an Eaa, or an aliphatic amino acid;~~

~~A^7 is an aromatic amino acid or an aliphatic amino acid;~~

A^8 is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid, or an aliphatic amino acid;

each of R_1 and R_2, is, independently, H or substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, heterocycle lower alkyl, E_1SO_2 or E_1CO wherein E_1, is aryl, aryl lower alkyl, heterocycle, or heterocycle lower alky and said substituent is halo, lower alkyl, hydroxy, halo lower alkyl, or hydroxy lower alkyl; and

R_3 is OH, NH_2, C_{1-12} alkoxy, or NH-Y-CH_2-Z, wherein Y is a C_{1-12} hydrocarbon moiety and Z is H, OH, CO_2H, or $CONH_2$, or R_3, together with the carbonyl group of A^8 attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl.

24 (currently amended): A compound of claim 23, wherein A^1 is an L-amino acid ~~and A^2 is a D aromatic amino acid~~.

25-26 (canceled)

27 (currently amended): A compound of claim [[25]] 24 of the formula:

~~H_2-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;~~

~~H_2-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;~~

H_2-Phe-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

H_2-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

(H)(CH_3CO)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

~~H_2-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH_2;~~

~~(H)(CH_3CO)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH_2;~~

~~(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH_2;~~

~~(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH_2;~~

~~H_2-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;~~

~~(H)(CH_3CO)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;~~

~~(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;~~

~~(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;~~

~~H_2-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH_2;~~

~~(H)(CH_3CO)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH_2;~~

~~(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH_2;~~

~~(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH_2;~~

H_2-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2;

(H)(CH_3CO)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2;

~~H_2-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2;~~ or

H_2-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2; or

a pharmaceutically acceptable salt thereof.

28 (currently amended): A compound of claim 23, wherein A^1 is a D-amino acid ~~and A^2 is a D-aromatic amino acid~~.

29-30 (canceled)

31 (currently amended): A compound of claim [[29]] 28 of the formula:

~~H_2-D-ß-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH_2;~~

~~H_2-D-ß-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;~~

~~H_2-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;~~

H_2-D-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2; or

H_2-D-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2; or

a pharmaceutically acceptable salt thereof.

32 (withdrawn-currently amended): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim [[18]] 23 or a pharmaceutically acceptable salt thereof.

33 (withdrawn-currently amended): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim [[18]] 23 or a pharmaceutically acceptable salt thereof.

34 (withdrawn-currently amended): A method of enhancing wound healing in a subject in need thereof, which

comprises administering to said subject an effective amount of a compound according to claim [[18]] 23 or a pharmaceutically acceptable salt thereof.

35 (withdrawn-currently amended): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim [[18]] 23 or a pharmaceutically acceptable salt thereof.

36 (canceled)

37 (withdrawn-currently amended): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim [[18]] 23 or a pharmaceutically acceptable salt thereof.

38-44 (canceled)

45 (new): A compound of the formula:

H_2-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2; or

H_2-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2; or a pharmaceutically acceptable salt thereof.

46 (new): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.

47 (new): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.

48 (new): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.

49 (new): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.

50 (new): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.